研究单位：[1]Shanghai Pharmaceuticals Holding Co., Ltd[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[3]Anhui provincial hospital,Hefei,Anhui,China[4]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[5]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China[6]Guangxi Cancer Hospital,Nanning,Guangxi,China[7]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[8]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China[9]Anyang Cancer Hospital,Anyang,Henan,China[10]Henan Cancer Hospital,Zhengzhou,Henan,China[11]Xiangyang Central Hospital,Xiangyang,Hubei,China[12]Jiangsu Province Hospital,Nanjing,Jiangsu,China[13]The First Affiliated Hospital of China Medical University,Shenyang,Liaoning,China[14]Linyi Cancer Hospital,Linyi,Shandong,China[15]The Second Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shanxi,China[16]Tianjin Medical University Cancer Institute & Hospital,Tianjin,Tianjin,China,300181
研究目的：
To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
